Yokoyama, Masahiro
Kusano, Yoshiharu
Nishihara, Anna
Inoue, Norihito
Nishimura, Noriko
Mishima, Yuko
Terui, Yasuhito
Nukada, Tomoyuki
Nomura, Takanobu
Hatake, Kiyohiko
Funding for this research was provided by:
Kyowa Hakko Kirin (n/a)
Article History
Received: 17 December 2018
Accepted: 5 April 2019
First Online: 15 May 2019
Compliance with ethical standards
:
: M Yokoyama reports personal fees (for consultancy) from Chugai Pharmaceutical, outside the submitted work; N Nishimura reports personal fees (for consultancy) from Chugai Pharmaceutical, outside the submitted work; Y Mishima reports personal fees (for consultancy) from Chugai Pharmaceutical, outside the submitted work; T Nukada and T Nomura report personal fees (for employment) from Kyowa Hakko Kirin, during the conduct of the study; K Hatake reports personal fees (for expert testimony) from Eisai and Otsuka Pharmaceutical, grants from AbbVie, Gilead Sciences, Celgene, Solasia Pharma, Pfizer, Bristol-Myers Squibb, Janssen Pharmaceutical, Ono Pharmaceutical, and Chugai Pharmaceutical, personal fees (for speakers’ bureau and others) from Takeda Pharmaceutical and Taiho Pharmaceutical, personal fees (for speakers’ bureau) from Celgene, and personal fees (for others) from Kyowa Hakko Kirin, outside the submitted work. Y Kusano, A Nishihara, N Inoue and Y Terui have nothing to disclose.
: The study has been approved by the appropriate institutional research ethics committee and has been performed in accordance with the ethical standards as described in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: For this type of study, formal consent is not required.